| A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis (VALOR) |
18 Years to 74 Years (Adult, Older Adult) |
California, Colorado, Florida, New York, Texas |
More Details; Priovant Therapeutics, Inc.; NCT05437263; Clinical Trial Administrator (646) 402-6892 |
| A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. (ALKIVIA) |
18 Years and older (Adult, Older Adult) |
United States |
More Details; Argenx; NCT05523167; Contact: Sabine Coppieters, MD 857-350-4834 |
| A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) |
The purpose of this study is to evaluate the efficacy and safety of Nipocalimab versus placebo in participants with active idiopathic inflammatory myopathies (IIM). 18 Years and older
|
Canada, Czechia, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Spain, United Kingdom, United States |
More Details; Janssen Research & Development, LLC; NCT05379634 |
| Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis |
18 years of age or older at the time of signing the informed consent. Body weight ≥ 30 kilograms at the time of Screening. Male or female. see more details |
Sites in US, Italy, Korea and Spain |
More details; Alexion Pharmaceuticals, Inc; 855-752-2356; NCT04999020 |
| Abatacept (Orencia) |
Active DM/PM/NM/JDM (over 18), overlap |
78 sites in US, Australia, S. America, Asia, Europe |
More details; BMS StudyConnect; NCT02971683 |
| Sodium thiosulfate for treatment of calcinosis associated with juvenile and adult dermatomyositis |
DM and JDM with calcinosis |
National Institutes of Health, Bethesda, MD |
More details; Adam Schiffenbauer 301-451-6270; NCT03267277 |
| IgPro20 (Hizentra) |
Active DM, ADM (over 18) |
94 sites in US, Australia, Japan, Argentina, Mexico, Europe, Ukraine, Russia |
More details; Trial Registration Coordinator 610-878-4000; NCT04044690 |